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CytokinesSutherlandia frutescens, one of the medicinal plants of southern Africa, has been widely used to boost the
immune system by various ethnic groups. This study aims to provide initial scientiﬁc evidence for in vitro
immune modulating activities of extracts of S. frutescens on cytokines, including interleukins 4, 6, 8, 10,
12p70 and TNF produced by the HL60 cell lines, as well as to identify possible compounds present therein.
This will assist in guiding further studies to an active compound. The chemical proﬁle of extracts, fractions
and compounds was determined using high performance liquid chromatography coupled tomass spectrometry.
Results from the initial in vitro experiments conducted indicated that extracts from S. frutescens possessed im-
mune modulating as well as anti-inﬂammatory activities. This in vitro study showed that an ethanolic extract
appeared to recruit the various inﬂammatory cytokines to the site of infection upon stimulation with phorbol
12-myristate 13-acetate, where essentially the non-polar compounds present in the ethanol extract contributed
to most of the activity observed for this extract.
© 2012 SAAB. Published by Elsevier B.V. All rights reserved.1. Introduction
Immunodeﬁciency is a condition in which the immune system, nor-
mally aﬁrst line of defence against unwanted pathogens, is unable to con-
tain infectious diseases. As a result, an immune-compromised individual
will often succumb tomore severe infections of longer duration than nor-
mal, causing the body to become chronically emaciated (Farlex, 2012).
Various plants have been used for a variety of medicinal purposes,
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Faleschini),
by Elsevier B.V. All rights reserveddrugs that are still in use today (Simpson and Ogorzaly, 2001). Several
immunomodulatory effects have been attributed to medicinal plants
(Actor and Dasgupta, 2003; Spelman et al., 2006), with great potential
for their use as pharmacological agents to treat immune disorders and
modulate immune-related pathogenesis (Clement-Kruzel et al., 2008).
Among these are Echinacea spp., Astragalus membranaceus, Zingiber
ofﬁcinale, Panax ginseng and Sambucus nigra (Dewick, 2002; Spelman
et al., 2006; Vukovic, 2004). Many scientiﬁc investigations have been
conducted on these plants to demonstrate their immune boosting
effects (Burger et al., 1997; Raduner et al., 2006; Spelman et al., 2006).
Botanicals have also been used to suppress an over reactive immune
system such as Siphonochilus aethiopicus (publication in process) and
the drug cyclosporine initially isolated from the fungus Tolypocladium
inﬂatum (Borel, 2002).
Southern Africa is rich in plant diversity and the use of traditional
medicines is widespread and promoted by the Ministry of Health. The
South African Department of Health has recommended two herbal
remedies (Hypoxis hemerocallidea and Sutherlandia frutescens) for
the management of many ailments, including cancer and for patients
with human immunodeﬁciency virus (HIV) infection (Mills et al.,
2005a).
S. frutescens, one of the most widely used indigenous plants of
southern Africa, is commonly found in the South West and Northern
Cape provinces (Fig. 1). It belongs to the family Fabaceae (pea and
bean or pod-bearing family). There are ﬁve Sutherlandia species.
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Sutherlandia tomentosa and Sutherlandia humilis. The genus took its
name from James Sutherland, ﬁrst director of the Edingburgh botanic
garden (Duncan, 2009). The term ‘sutherlandia’ refers to a shrubby
plant that is known by many different names including cancer bush,
umnwele (Xhosa), Insiswa (Zulu), and Phetola (Sotho) (Jackson,
1990). Various tribes have used this plant for medicinal purposes,
particularly chronic diseases, including cancer (Van Wyk and
Albrecht, 2008). This study was undertaken to provide a scientiﬁc
basis to support the use of this plant amongst traditional healers for
immune-compromised and cancer-infected individuals.
Literature reports have also indicated that extracts from S. frutescens
can also be used in the treatment of HIV/AIDS (Harnett et al., 2005;Mills
et al., 2005b), cancer (Chinkwo, 2005; Stander et al., 2007; Tai et al.,
2004) as well as to treat diabetes (Chadwick et al., 2007; Sia, 2004).
The anti-cancer and anti-viral properties of extracts from S. frutescens
have been attributed to the presence of L-canavanine (Green, 1988).
In addition, extracts have also been shown to have anti-bacterial,
anti-oxidant (Katerere and Eloff, 2005), anti-inﬂammatory (Kundu et
al., 2005) and anti-mutagenic (Reid et al., 2006) activities. Ngcobo
(2008) showed that low concentrations of extracts of S. frutescens on a
primary culture of T cells could stimulate immune cells.
A number of various in vivo and in vitro techniques exist to study im-
mune modulation of natural products for example the in vivo use of
ﬂow cytometry and immunohistochemistry in a standard primate tox-
icology evaluation for the diagnosis of potential immunomodulatory ef-
fects (Lappin and Black, 2003) or the in vitro stimulation of cytokine
production in lipopolysaccharide (LPS)-induced cells (Clement-Kruzel
et al., 2008; Raduner et al., 2006; Spelman et al., 2006; Zidek et al.,
2009). Numerous alternative techniques are available to assess the im-
mune modulation of natural products (Haddad et al., 2005; McKay and
Blumberg, 2007; Spelman et al., 2006;Wagner, 1990). The technique of
using stimulated cytokine expression in various immune cells has been
widely used. Spelman et al. (2006) suggested that the immune modu-
lating effects of the botanical medicines reviewed may be due to cyto-
kine modulation. Additionally, the review article from Zidek et al.
(2009) has concluded that cytokine and anti-cytokine immunother-
apies have proved to provide valuable therapeutic effects. As such,mod-
ulation of cytokine secretion may offer alternative approaches in the
treatment of a variety of diseases, especially in immune-compromised
patients (Spelman et al., 2006). Novel therapeutic strategies targeting
the cytokine network are needed to enhance the effectiveness of cur-
rent immunotherapeutic procedures (Zidek et al., 2009). Cytokines
are key mediators in an immune response (IR), which are produced
by cells of the immune system in response to a stimulus and help to re-
cruit or orchestrate other immune cells to the site of infection (LydyardFig. 1. Geographical distribution of Sutherlandia species throughout South Africa on the left
Reserve, Springbok, Northern Cape (photo taken by N. Harding).et al., 2004; O'Gorman and Donnenberg, 2008; Parkin and Cohen, 2001).
However, the effectiveness of immunotherapies may vary since, the bi-
ological effects of several cytokines are often overlapping and individual
cytokines possess multiple regulatory functions. The enhancement of
efﬁcacy of immunotherapeutic treatments may therefore lead only
through more complex and novel strategies (Zidek et al., 2009). It is
therefore important that such studies should assay a variety of cyto-
kines as well as assess various other factors involved in the immune re-
sponse. Follow up in vivo evaluations should be coupled to such
research activities.
This research aims to show preliminary in vitro immune modula-
tion activities of extracts prepared from fresh and dried S. frutescens
plant material, using an HL60 model system with stimulated cytokine
quantiﬁcation; as well as to identify possible active compounds in the
extracts using high performance liquid chromatography–mass spec-
trometry (HPLC–MS) analysis. HPLC is a powerful and versatile ana-
lytical technique used to obtain chromatographic proﬁles of plant
extracts (Holme and Peck, 1998; Hostettmann et al., 2010; Wolfender,
2009); while MS, coupled to HPLC, allows for information on the identity
and structure of the components therein. In the drug development pro-
cess, MS has been used for lead compound discovery, structural analysis,
synthetic development, combinatorial chemistry, pharmacokinetics and
drug metabolism (Pavia et al., 2009). While a number of various review
articles have contrasted the limitations as well as the potential of
HPLC–MS (Goetzinger et al., 2004; Marston and Hostettmann,
2009; Wolfender, 2009), it nevertheless remains one of the most
widely and frequently used techniques in the study of natural
products, particularly where separation, identiﬁcation and quanti-
ﬁcation of compounds present in a given sample is concerned
(Marston and Hostettmann, 2009). A study done by Avula et al.
(2010) also employed the use of HPLC–MS to conﬁrm the presence
of the previously isolated compounds (Fu et al., 2008, 2009) found
in S. frutescens; this technique has therefore been employed in this
study as well. As such, the reported outcomes of this paper will
serve to guide future researchers to pay more attention to the ‘ac-
tive regions’ of the HPLC–MS chromatograms to ultimately isolate
the active compound(s).
2. Materials and methods
2.1. Chemicals
CP grade solvents were purchased fromMerck and distilled before
use. Solid phase extraction C-18 cartridges (Supelco 140 ml PP tubes)
were purchased from Sigma Aldrich. Distilled water was used for all
procedures. HPLC-grade solvents were purchased from Microsep(sahealthinfo.org) and on the right S. frutescens growing in the wild at Goegap Nature
Table 1
Gradient timetable for the HPLC-SQD method used.
Time (min) Flow rate (ml/min) % A FA H2O % B MeOH % C ACN
0 0.3 95 5 0
4 0.3 95 5 0
5 0.3 75 25 0
27 0.3 55 45 0
30 0.3 42 58 0
70 0.3 22 78 0
80 0.3 12 88 0
85 0.3 12 88 0
90 0.3 0 100 0
100 0.3 0 100 0
107 0.3 0 0 100
113 0.3 0 0 100
115 0.3 95 5 0
50 M.T. Faleschini et al. / South African Journal of Botany 85 (2013) 48–55(Romil pure chemistry solvents). RPMI-1640, foetal bovine serum
(FBS) and L-glutamine were purchased from Whitehead Scientiﬁc.
Gentamicin, phorbol 12-myristate 13-acetate (PMA) and etoposide
were purchased from Sigma Aldrich. The Cytometric Bead Array™
Human Inﬂammation Cytometric Bead array (CBA) kit (551811)
was purchased from Beckton Dickinson (BD) Biosciences and
analysed using BD Biosciences' equipment and software.
2.2. Plant collection
S. frutescens (L.) R. B.r. plant material was collected from a cultiva-
tion site in the Free State, South Africa (GPS coordinates: 29° 6.774′ S;
25° 24.305′ E). Identiﬁcation of the specimen deposited at the South
African National Biodiversity Institute (SANBI), Tshwane was con-
ﬁrmed (SANBI voucher specimen number: 428679).
2.3. Extract preparations
Fresh leaves (488 g) were boiled in 12.5 l of H2O for 1 h with oc-
casional stirring. The suspension was then ﬁltered and freeze-dried.
The aqueous extract from the fresh leaves was labelled extract A
(47.8 g; 9.8% yield). The air-dried leaves (200 g) were extracted
with ethanol (EtOH; 1.6 l of 96% v/v) at room temperature, stirred,
left overnight and then ﬁltered and evaporated to give extract B
(11.17 g; 55.9% yield). Another 200 g of the air-dried leaves was
boiled in 2.0 l of H2O for 1 h with occasional stirring. This solution
was ﬁltered and freeze-dried (extract C, 33.72 g; 16.9% yield).
2.4. Preparation of fractions
The ethanol extract B was fractionated using solid phase cartridges.
10 g of extract B (EtOH) was dissolved in 20 ml H2O and loaded on the
activated C-18 (Supelco 140 ml PP tubes, Sigma Aldrich) cartridge. Dif-
ferent solvents were used to generate the fractions: 200 ml 100% H2O,
160 ml 20% MeOH, 110 ml 40% MeOH, 160 ml 60% MeOH, 160 ml
80% MeOH, 200 ml 100% MeOH and 200 ml 100% acetonitrile (ACN).
The resulting fractions were evaporated and freeze dried and combined
to give fractions I to III according to TLC proﬁles.
2.5. Quantiﬁcation of cytokines with CBA
The HL60 cell line was obtained from the European collection of cell
culture (ECACC) andmaintained in suspension at 37 °C in 5% carbon di-
oxide (CO2) and 100% relative humidity in RPMI-1640 supplemented
with 5% foetal bovine serum (FBS), 2 mM L-glutamine and 50 μg/ml
gentamicin. Cells were counted and inoculated in a 96-well microtitre
plate at plating densities of 7000 to 10 000 cells per well and incubated
for 24 h. Test samples (50 μl) were added to speciﬁc wells at a concen-
tration of 25 μg/ml and incubated for 48 h. Phorbol 12-myristate
13-acetate (PMA) (12.5 ng/ml) was used as a cytokine stimulant and
added to the wells at 42 h, where needed, and placed in the incubator
for the remaining 6 h. Cells without drug addition served as the control,
while the blank contained complete cell culture media without cells.
Ethanolic preparations of Echinacea spp. and S. aethiopicus were used
as positive (immune boosting) and negative (immune suppressant)
controls respectively, and were also tested with and without PMA.
After 48 h of incubation, the plate was removed and centrifuged for
2 min at 1000 g, supernatants (50 μl) from each well were removed
and placed in Eppendorf tubes separately.
The IL12p70, TNF, IL10, IL6, IL1β and IL8 cytokines were detected
using the human inﬂammation Cytometric Bead Array (CBA) kit
(551811; BD Biosciences). Tests were performed according to the
manufacturer's instructions available online. The six bead populations
are resolved in a red channel of a BD FACSCalibur ﬂow cytometer. For
each set of experiments, a standard curve was generated. The results
were expressed as pg/ml and then analysed for their relativeexpression (control versus treated samples). The lower limit for de-
tection for each cytokine was determined as 10 pg/ml. In order to
simplify results from the assays a numbering system as outlined in
Table 2 was used.
2.6. Statistical analysis
All determinations were done in quadruplicate, and the results
were reported as mean±standard deviation (sd). Graphs were plot-
ted using Origin version 6.0 (Microcal Software, Inc.).
2.7. HPLC MS analysis
For each extract and fraction, approximately 25 mgwasweighed out
into a vial and 2 ml of HPLC-grade solvent (methanol, acetonitrile or
water depending on the solubility of the sample) was added. This mix-
ture was then put in an ultrasonic bath for 10 min and ﬁltered through
Acrodisc GHP syringe ﬁlters, before being placed into 2 ml HPLC vials.
The various samples were analysed using a WATERS 2695 HPLC separa-
tion module. Two Atlantis T3 columns (10×250 mm, 5 μ particle size)
connected in series, were used for the separation. UV–VIS detection
was done on a WATERS PDA scanning from 200 to 600 nm. The mobile
phase used was 0.1% (v/v) formic acid in water (A), methanol (B) and
acetonitrile (C). The ratio of mobile phase prepared is given in Table 1
below. Additionally, mass spectrometry detection was performed using
a WATERS SQD scanning from 100 to 1200 m/z with polarity (+/−)
switching with a scan time of 0.20 s. The operating conditions in the
ESI source were as follows: source temperature, 150 °C; desolvation
temperature, 450 °C; capillary voltage, 3.00 kV; cone voltage, 30.0 V.
Gas ﬂow (N2): desolvation, 800 l/h; cone gas, 10 l/h.
2.8. Isolation of compounds
Sutherlandioside B was a kind gift from Prof. Albrecht, while
sutherlandiosides A and D (Fig. 2) were isolated from the plant
extract following the procedure described by Fu et al. (2008).
Only a small amount of the compounds was isolated and therefore
no further biological activity was able to be conducted on them. For
structure elucidation of the compounds, NMR spectroscopy was
performed using a 600 MHz Varian NMR.
Accurate mass analysis was performed on a WATERS Synapt G1
UPLC-TOF-MS system. Two column types were used namely, WATERS
Acquity CSH C18 (150×2.1 mm, particle size: 1.7 μ) for the polar com-
pounds and WATERS Acquity HSS T3 (150×2.1 mm, particle size:
1.8 μ) for the more polar compounds.
3. Results and discussion
The extracts and fractions of S. frutescens were analysed for their
activities on the release of cytokines with PMA as a co-stimulant on
Table 2
Numerical values corresponding to the various samples used in the cy-
tokine quantiﬁcation assay.
Number Sample
1 Control (Ctrl.)
2 PMA (12.5 ng/ml)
3 Extract A (fresh leaves)
4 A+PMA
5 Extract B (EtOH)
6 B+PMA
7 Extract C (dry leaves)
8 C+PMA
9 Fraction I
10 I+PMA
11 Fraction II
12 II+PMA
13 Fraction III
14 III+PMA
15 Echinacea (Ech)
16 Ech+PMA
17 Siphonochilus aethiopicus (Sa)
18 Sa+PMA
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Fig. 2. Structures of sutherlandiosides A, B and D are respectively referred to as com-
pounds 1, 2 and 3.
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recruited to the sites of inﬂammation and appropriately activated.
This is achieved by cellular receptors and associated cytokines that bind
to these receptors (Lydyard et al., 2004; O'Gorman and Donnenberg,
2008; Parkin and Cohen, 2001). The cytokines IL1β, IL6, IL10, IL12p70,
IL8 and TNF, used in this assay, were selected due to their role in var-
ious pro- and anti-inﬂammatory actions involved in the ﬁrst step of
the IR i.e. inﬂammation.
From the results of the six cytokines analysed, in the above in vitro
experiment, no effect was found on IL1β, IL6, IL10 and IL12p70 (as
depicted in Fig. 3), therefore the following section will be focussed
on the change in TNF and IL8 only (Fig. 4a and b, respectively). In
this experiment three controls were used namely, the blank control
(number 1 in Figs. 3, 4a and b), a positive control (Echinacea extract,
number 15 in Figs. 3, 4a and b) and a negative control (S. aethiopicus
extract, number 17 in Figs. 3, 4a and b). No release of any of the six
cytokines (i.e., initiation of an immune response) was observed
when all the extracts and fractions of S. frutescens were applied to
the HL60 cells without the co-stimulation of PMA (represented by
odd numbers in Figs. 3, 4a and b). When PMA (number 2 in Fig. 4a
and b) was added to the cell culture system alone, there was a higher
production of IL8 (4551.95±410.85 pg/ml) and an improvement in
the amount of TNF (129.69±19.21 pg/ml) being released into the su-
pernatant when compared to the blank control (which had a concen-
tration of 50.83±7.74 pg/ml).
Speciﬁcally fraction III from the ethanol extract; together with PMA
(number 14 in Fig. 4a and b), contributed to amarked increased release
of the TNF and IL8 cytokines (229.45±13.89 for TNF and 5967.93±
226.86 pg/ml for IL8). The aqueous extracts and fractions I and II, to-
gether with PMA, displayed a marked decrease of IL8 being released
(concentrations ranging from about 2909 to 3260 pg/ml). As is appar-
ent in Fig. 3, it was observed that the S. frutescens extracts did not affect
subsequent release of IL1β, IL6, IL10 and IL12p70 in the culture system,
relative to PMA, after a 48 h incubation period (concentrations varied
from 3 to 20 pg/ml).
To correlate the activities found with the in vitro cytokine experi-
ment, all extracts were then analysed using HPLC–MS to obtain their
chromatographic proﬁles. The resulting proﬁles of extracts A, B and C
in ESI− (electrospray ionisation negative mode) are shown in Fig. 5,
while those for fractions I, II and III in ESI+ are given in Fig. 6. The
cycloartane glycosidic compounds — sutherlandioside A, B and D —
were isolated from an extract of S. frutescens and identiﬁed in the
HPLC–MS proﬁles of the resulting extracts and fractions. In the chro-
matographic proﬁle of extract B they were found to elute at 57.24,
43.51 and 59.25 min, respectively (labelled 1, 2 and 3 in Figs. 5 and6). A higher amount of these compounds can be found in fraction II rel-
ative to the other fractions (Fig. 6). From the chromatographic proﬁles
of the fractions it can be extrapolated that themajority of thepolar com-
pounds can be found in fraction I and the aqueous extracts (extracts A
and B, Figs. 5 and 6), which could be mainly made up of ﬂavonol glyco-
sidic compounds similar to the ones isolated by Fu et al. (2009), due
to their similar interaction with the column used as well as their
similar mass fragmentation patterns obtained from HPLC–MS analysis.
A structural analysis, which included MS interpretation, UV analysis
and a 3D structure evaluation, was conducted on fraction I to predict
the possible compounds present in order to provide some justiﬁcation
that these compounds might be the ﬂavonol glycosides. A ﬂavonoid
detection technique using ferric (iii) chloride hexahydrate showed the
presence of a higher concentration of ﬂavonoids in fraction I. The
cycloartane glycosidic compounds (which were isolated, identiﬁed
and evaluated on the HPLC–MS) were found in higher quantities in
fraction II as well as extract C,while the non-polar compounds appeared
in fraction III. The method described by Avula et al. (2010) showed the
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Fig. 4. Release of TNF (a) and IL8 (b) for the blank control, PMA (at 12.5 ng/ml), extracts A
to B, fractions I to III, positive and negative controls at 25 μg/ml for a 48 h incubation
period. For statistical analysis n=4.
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2008) were found to elute from around 24 to 30 min (themore interme-
diate polarity region of their chromatographic proﬁle). By evaluating the
isolated sutherlandioside A, B and C compounds on the HPLC–MS
these results concur with the above method that the cycloartane
glycosides were also found in the intermediate polarity region
(from about 35 to 60 min) from the chromatographic proﬁles
obtained of the extracts and fractions (Figs. 5 and 6). The surround-
ing compounds in this region also possess mass fragmentation pat-
terns similar to these compounds, thus proposing that this region
mainly contains the sutherlandiosides and other related com-
pounds of intermediate polarity. No biological activity was
conducted on the isolated compounds as there were insufﬁcient
amounts.
PMA (acting as a mitogen) was used as an initiator of the increased
release of cytokines into the culture supernatant, which was taken as a
measure of immune response initiation potential (Fig. 4a and b, sample
number 2). This arrangement resulted in a co-stimulated release of TNF
and IL8 into the culture supernatant well above that of the baseline
levels found with the blank control.
As PMA forms part of the lipopolysaccharide (LPS) of gram nega-
tive bacterial cells, it can be recognised by pattern recognition recep-
tors (PRR) present on the target cells used in this study (Lydyard et
al., 2004). As such, the expression of TNF is stimulated by LPS interac-
tion with PRR on the HL60 cell line and subsequently IL8 is activated
by the release of TNF. TNF activation is consequently coupled with
programmed cell death (apoptosis) initiated by infection with a par-
ticular pathogen and also coincides with the release of inﬂammatory
mediators which stimulate recruitment of other immune cells to the
site of infection (Lydyard et al., 2004). The release of IL8 is believed
to help the immune system to increase chemotaxis for neutrophils
(as well as for T cells and basophils) at the site of inﬂammation
(Lydyard et al., 2004; Parkin and Cohen, 2001).
In contrast to the PMA alone, the effect of fraction III from the eth-
anol extract (containing mostly the non-polar compounds as shown
in Fig. 6) on the target cells, with the co-stimulation of PMA, exhibited
a greater release of TNF and IL8 into the culture supernatant. In es-
sence, this observed effect, together with the up-regulated release
of speciﬁc cytokines, could be taken to mimic a possible in vivo situa-
tion of a bacterial infection in a given host, being combated by the re-
lease of appropriate cytokines. A study conducted by Katerere and
Eloff (2005) provided concurrent results that anti-staphylococcal ac-
tivity resided in the non-polar fractions. Not much focus has been
given to the isolation and identiﬁcation of the non-polar compounds
found in Sutherlandia species as most of the focus has been on theﬂavonol- and the cycloartane glycosidic compounds; therefore further re-
search into the isolation and identiﬁcation of pure compounds from the
non-polar region should be conducted.
The decreased inﬂuence of S. frutescens extracts on the release of
IL8, together with the co-stimulation by PMA in the in vitro cell cul-
ture system, was mainly found in the aqueous extracts. According to
the method described by Avula et al. (2010) it was found that the ﬂa-
vonol glycosides (sutherlandins A to D, isolated by Fu et al., 2009)
were found to elute from around 8 to 12 min (the polar region of
their chromatographic proﬁle). The chromatographic proﬁles of the
extracts and fractions obtained here, together with the low interac-
tion between polar compounds and the column stationary phase as
well as resulting mass fragmentation patterns of the compounds elut-
ing in the polar region of the extracts (from about 15 to 25 min), col-
lectively suggest that these compounds could be those of the ﬂavonol
glycosides, or related compounds found in Sutherlandia species. There-
fore, the observed effect of the aqueous extracts plus fraction I could
Extract A 
Extract B 
Extract C 
1 32
Fig. 5. The HPLC ESI− chromatograms for extracts A, B and C. 1, 2 and 3 in the chemical proﬁle of extract B indicates the presence of sutherlandiosides A, B and D, respectively.
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interactions with cells of the in vitro cell culture system.
As stated above, IL8 plays a role in inﬂammation and therefore
the reduction of IL8 found with the aqueous extracts could possibly
be related to the anti-inﬂammatory properties of S. frutescens.
Fernandes et al. (2004) have indicated that a hot water extract
of S. frutescens possessed superoxide, aswell as hydrogenperoxide scav-
enging activities. This could account for some of the anti-inﬂammatory
properties that have been described in the literature. In addition, while
anti-inﬂammatory properties associated with various medicinal plant
extracts have been explained, at least in part, by their anti-oxidant activ-
ities (Gali-Muhtasib et al., 1999;Gerritsen et al., 1995; Lindsey et al., 2002;
Schinella et al., 2002), extracts from S. frutescens have also been
demonstrated to have anti-oxidant activity in reducing free radical
cations (Tai et al., 2004). In addition, Kundu et al. (2005) have
shown that a methanolic extract of S. frutescens possessed anti-
inﬂammatory activity by inhibiting 12-O-tetradecanoylphorbol-
13-acetate (TPA)-induced COX-2 expression in both in vitro and
in vivo models of carcinogenesis. Collectively, all these ﬁndings
have provided mechanistic support to the effect that plant extracts,
via their active constituents connected with anti-inﬂammatory
properties, also demonstrate anti-tumour promoting potential as
well.
A noteworthy observation from this in vitro experimentwas that for
immune boosting effects, an ethanolic preparation would have been
more beneﬁcial. Similarly, for an anti-inﬂammatory response, an aque-
ous preparation could have achieved better results. Further researchaccordingly needs to be conducted in this direction. An ethanolic extract
of S. frutescens was shown to exhibit no signiﬁcant anti-oxidant effects
(Tai et al., 2004). However, aqueous extractswere shown to possess sig-
niﬁcant anti-inﬂammatory and anti-oxidant effects (Fernandes et al.,
2004; Katerere and Eloff, 2005; Kundu et al., 2005). A study done by
Ngcobo (2008) showed that high concentrations of aqueous as
well as ethanol extracts of S. frutescens, could reduce the produc-
tion of IL1β and TNFα, which are regarded as being helpful in
ﬁghting muscle wasting associated with cancer and HIV/AIDS pa-
tients. Anti-inﬂammatory agents have also been shown to exhibit
chemo-preventative activity (Surh et al., 2001; Surh, 2002); therefore,
the anti-inﬂammatory properties attributed to the aqueous extracts of
S. frutescens could possibly be used in a chemo-preventative setting as
well.
The differential increase in IL8, together with the co-stimulation
by PMA, of the non-polar compounds found in the ethanol extract,
could also have contributed to possible immune stimulating effects.
For this reason, preparations of Sutherlandia seem to exhibit many at-
tributes that could be related to the complex nature of compounds
present in the raw plant material. The different varieties of com-
pounds present in the various extracts of S. frutescens, therefore pro-
vide initial ﬁndings that support its various traditional uses. However,
further in vitro and in vivo studies would be required to conﬁrm this
supposition. The aqueous extracts displayed a similar effect as the
positive control (Echinacea) (Burger et al., 1997; Raduner et al.,
2006; Sharma et al., 2010; Spelman et al., 2006; Vukovic, 2004),
while the negative control (S. aethiopicus) displayed a complete
Fraction I 
Fraction II 
Fraction III 
1
2
3
Fig. 6. HPLC ESI+ chromatograms for fractions I, II and III.
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thus demonstrating immunosuppressive potential of extracts from
this plant. S. aethiopicus has been known to have immunosuppressive
characteristics by suppressing the production of certain cytokines
needed for the immune response, such as IL8 (publication in process).
The plant contains an active furanoterpenoid compound that is
known to inhibit the nuclear transcription factor NF-κB involved in
the regulation of many pro-inﬂammatory factors.
4. Conclusion
The results from the above in vitro experiment have provided initial
evidence that the non-polar compounds, present in the ethanol extract
of S. frutescens, could suggestively amplify the release of speciﬁc,
immune-modulating cytokines, particularly by cells already stimulated
by a pathogenic micro-organism, such as a gram negative bacterium.
These results have also indicated that the cultured cells need to be in
a condition where they were intrinsically releasing certain cytokines,
so that when an a-polar fraction of an ethanolic preparation was subse-
quently added, such as to HL60 cells, they were able to up regulate and
releasemore of the particular cytokines involved in the IR. This could be
of great interest for the treatment of diseases that speciﬁcally attack the
immune system, such as HIV/AIDS and cancer, resulting in amore rapid
expulsion of the invadermicro-organism, with subsequent limitation of
the likelihood of further spread of the infectious agent to surrounding
cells. HPLC–MS analysis also made it possible to determine that the
non-polar compounds were more helpful at stimulating the in vitro im-
mune system, while the aqueous extracts (more polar compounds)
were found to precipitate an anti-inﬂammatory type response. Overall,
from the initialﬁndings of the cytokine assay, particular attention needsto be given to the correct choice of solvent used for an extract prepara-
tion of S. frutescens, in order to select for a speciﬁc biological effect. Al-
though this research had a limitation of testing the roles of pure
compounds isolated from the S. frutescens, thismanuscript acts as an in-
sightful perspective to the active regions of the extracts of S. frutescens
for further isolation of pure compounds. At the moment, the research
group is busy in isolation and identiﬁcation of pure compounds from
extracts of S. frutescens, especially focussing on the non-polar region
(the active section). The results of this study will be reported soon.
Supplementary investigations into isolation and identiﬁcation of
the non-polar compounds (present in the non-polar region of the
ethanol extract) could be of great value in future studies of this
kind, especially where various in depth in vivo immune stimulating
models and animal studies are concerned.
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